Anti-FADD antibody (ab24533)
Key features and details
- Rabbit polyclonal to FADD
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-FADD antibody
See all FADD primary antibodies -
Description
Rabbit polyclonal to FADD -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide:
KIDSIEDRYPRNLTERVRESL
, corresponding to amino acids 125-145 of Human FADD (Peptide available as ab54083.) -
General notes
This product is manufactured by BioVision, an Abcam company and was previously called 3039 FADD Antibody. 3039-100 is the same size as the 100 µg size of ab24533.
FADD has a molecular weight of 23kDa with an apparent molecular weight of 28 kDa on SDS-PAGE.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 1% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Primary antibody notes
FADD has a molecular weight of 23kDa with an apparent molecular weight of 28 kDa on SDS-PAGE. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab24533 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 23 kDa.
|
Notes |
---|
WB
Use at an assay dependent concentration. Predicted molecular weight: 23 kDa. |
Target
-
Function
Apoptotic adaptor molecule that recruits caspase-8 or caspase-10 to the activated Fas (CD95) or TNFR-1 receptors. The resulting aggregate called the death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation. Active caspase-8 initiates the subsequent cascade of caspases mediating apoptosis. -
Tissue specificity
Expressed in a wide variety of tissues, except for peripheral blood mononuclear leukocytes. -
Sequence similarities
Contains 1 death domain.
Contains 1 DED (death effector) domain. -
Domain
Contains a death domain involved in the binding of the corresponding domain within Fas receptor. - Information by UniProt
-
Database links
- Entrez Gene: 8772 Human
- Omim: 602457 Human
- SwissProt: Q13158 Human
- Unigene: 86131 Human
-
Alternative names
- FADD antibody
- FADD protein antibody
- FADD_HUMAN antibody
see all
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (23)
ab24533 has been referenced in 23 publications.
- Wu S et al. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms. Cell Biol Toxicol 39:237-258 (2023). PubMed: 34713381
- Madka V et al. Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the Apcmin/+ mouse model. Am J Cancer Res 12:2118-2131 (2022). PubMed: 35693092
- Cavalcante RS et al. STAT3/NF-?B signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. Br J Pharmacol 178:2284-2304 (2021). PubMed: 33434950
- Liang X & Ju J Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK. Oncol Rep 45:N/A (2021). PubMed: 33786627
- C de S L Oliveira AL et al. Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer. Pharmaceutics 12:N/A (2020). PubMed: 32102251